期刊文献+

地胆草三萜提取物对S180小鼠体内抗肿瘤作用的实验研究 被引量:1

Anti-Tumor Effects of Triterpene Extraction from Elephantopus scaber Linn. on S180 Tumor-Bearing Mice
下载PDF
导出
摘要 我们通过建立S180荷瘤模型,探索地胆草提取物对S180实体瘤的抗肿瘤研究。通过对健康雄性小鼠接种S180肉瘤随机分成对照组、环磷酰胺组以及地胆草提取物低、中、高剂量组,给药后观察探索荷瘤鼠的抑瘤率、小鼠存活时间以及胸腺和脾脏指数。结果研究表明地胆草提取物对S180实瘤小鼠具有一定的抑瘤效果:地胆草提取物高剂量组的抑瘤率为44.12%;荷瘤鼠的生存率提高至36.27%;对S180荷瘤鼠的胸腺指数和脾脏指数有一定的提高,在一定程度上能有效提高S180荷瘤鼠的免疫能力。 We explored the inhibiting effects of triterpene extraction from Elephantopus scaber Linn. by establishing S180 tumor-bearing mice model. Forty mice were randomly assigned into five groups which were the control group, cyclophosphamide group, low dose Elephantopus scaber Linn. group, middle dose Elephantopus scaber Linn. group, and high dose Elephantopus scaber Linn. group. The inhibitory rate and survival rate of S180 tumor bearing mice were observed as well as the thymus and spleen index after administration. The research results showed that the high dose triterpene extraction from Elephantopus scaber Linn. could prolonged the survival time of S180 tumor bearing mice which increased up to 36.27% and the inhibition rate was up to 44.12%. And the results of the thymus and spleen index of the experimental group showed that the triterpene extraction from Elephantopus scaber Linn. could inhibit the growth of the S180 solid tumor.
作者 廖建华 Jianhua Liao(School of Pharmaceutical Sciences, Gannan Medical University, Ganzhou Jiangxi)
出处 《药物化学》 2018年第2期37-41,共5页 Hans Journal of Medicinal Chemistry
基金 江西省卫生厅科技计划项目(2013A043) 校级课题(YB201319)资助。
关键词 抗肿瘤 三萜提取物 地胆草 羽扇豆醇 S180 Anti-Tumor Triterpene Extraction Elephantopus scaber Linn Lupeol S180
  • 相关文献

参考文献4

二级参考文献39

  • 1阮期平,赵莉,陈吉森.附子多糖FI的分离纯化及生物学活性研究[J].四川生理科学杂志,2000,22(2):40-41. 被引量:6
  • 2陈玉春.人参、附子与参附汤的免疫调节作用机理初探[J].中成药,1994,16(8):30-31. 被引量:54
  • 3杨金明,郭红梅.黄芪对S1802荷瘤小鼠的免疫增强及抑瘤作用[J].中国实验临床免疫学杂志,1995,7(1):41-44. 被引量:20
  • 4周远鹏 李文化.附子的强心有效成分之一:去甲乌药碱的实验及临床研究概况[J].中国药理与临床,1992,8(8):43-48.
  • 5LI Huschtscha, WA bartuier, CE Anderson Ross, et al.Characteristics of cancer cell death after exposure to cytotoxic drugs in vitro[J]. Br J Can, 1996,73:54-60.
  • 6Parkin DM, Bray F, Ferlay i, et al. Global cancer statistics, 2002[J]. CA Cancer J Clin,2005,55(2) : 74-108.
  • 7Gish RG, Baron A. Hepatocellular carcinoma (HCC): current and e-volving therapies[J]. Drugs,2008, 11(3) : 198-203.
  • 8Verslype C,Van Cutsem E, Dicato M,et al. The management of hep-atocellular carcinoma. Current expert opinion and recommendations de-rived from the 10th World Congress on Gastrointestinal Cancer, Barce-lona, 2008[ J]. Ann Oncol,2009 , 20 (Suppl 7) : il-i6.
  • 9Rampone B,Schiavone B,Confuorto G. Current management of hepa-tocellular cancer[J]. Curr Oncol Rep,2010, 12(3) : 186-192.
  • 10Kurahashi N, Inoue M, Iwasaki M,et al. Vegetable, fruit and antioxi-dant nutrient consumption and subsequent risk of hepatocellular carci-noma: a prospective cohort study in Japan[ J]. Br J Cancer,2009, 100(1): 181-184.

共引文献120

同被引文献13

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部